Loading..

Cytokinetics, Incorporated (CYTK) Report Analysis

Corporate Events

Positive

Cytokinetics, Incorporated Provides Update on N...

2022-06-17 11:36:00

On June 17, 2022, Cytokinetics, Incorporated announced that, in response to a request from the U.S. Food and Drug Administration (FDA), the co...

Positive

Cytokinetics Announces Start of Open-Label Exte...

2022-06-16 11:30:00

Cytokinetics, Incorporated announced the start of COURAGE-ALS OLE (Clinical Outcomes Using Reldesemtiv on ALSFRS-R in a Global Evaluation in A...

Positive

Cytokinetics, Incorporated Announces Additional...

2022-06-13 11:30:00

Cytokinetics, Incorporated announced that additional data from a new analysis of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in O...

Neutral

Cytokinetics, Incorporated Presents at 33rd ann...

2022-06-13 11:30:00

Cytokinetics, Incorporated Presents at 33rd annual scientific session, Jun-10-2022 .

Neutral

American Society Of Echocardiography Incorporat...

2022-06-07 12:48:00

American Society Of Echocardiography Incorporated, 33rd annual scientific session, Jun 10, 2022 through Jun 13, 2022.

Neutral

Cytokinetics, Incorporated Presents at The JMP ...

2022-06-02 20:00:00

Cytokinetics, Incorporated Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 03:00 PM. Venue: Lotte New York Palace, 4...

Neutral

Cytokinetics, Incorporated Presents at Goldman ...

2022-06-02 20:00:00

Cytokinetics, Incorporated Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-13-2022 02:40 PM. Venue: Terranea Resort, R...

Neutral

Cytokinetics, Incorporated Presents at 2022 Jef...

2022-06-02 20:00:00

Cytokinetics, Incorporated Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 10:00 AM. Venue: Marriott Marquis, New York Ci...

Neutral

Cytokinetics, Incorporated has filed a Shelf Re...

2022-05-31 00:00:00

Cytokinetics, Incorporated has filed a Shelf Registration in the amount of $318.12826 million. Security Name: Common Stock Securities Offe...

Neutral

Cytokinetics, Incorporated Presents at ALS Drug...

2022-05-30 11:39:00

Cytokinetics, Incorporated Presents at ALS Drug Development Summit, May-24-2022 through May-26-2022. Venue: Boston, United States. Presentatio...

Neutral

Cytokinetics, Incorporated Presents at H.C. Wai...

2022-05-17 20:00:00

Cytokinetics, Incorporated Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM. Venue: Fontainebleau Miami Bea...

Neutral

Cytokinetics, Incorporated - Shareholder/Analyst Call

2022-05-03 20:00:00

AGM

Neutral

Cytokinetics, Incorporated, Q1 2022 Earnings Ca...

2022-04-20 20:00:00

Cytokinetics, Incorporated, Q1 2022 Earnings Call, May 04, 2022

Neutral

Cytokinetics, Incorporated to Report Q1, 2022 R...

2022-04-20 20:00:00

Cytokinetics, Incorporated announced that they will report Q1, 2022 results at 4:00 PM, US Eastern Standard Time on May 04, 2022

Negative

Cytokinetics, Incorporated Announces Retirement...

2022-04-15 20:34:00

On April 12, 2022, Mark A. Schlossberg, Senior Vice President, Legal, General Counsel and Secretary of Cytokinetics, Incorporated, informed Cy...

Neutral

Cytokinetics, Incorporated, Annual General Meet...

2022-04-08 20:06:00

Cytokinetics, Incorporated, Annual General Meeting, May 10, 2022, at 10:00 Pacific Daylight. Location: at its headquarters, 350 Oyster Point B...

Negative

Cytokinetics, Incorporated Announces Changes to...

2022-04-08 11:30:00

Cytokinetics, Incorporated announced changes to its Board of Directors. L. Patrick Gage, Ph.D., Chairman of the Board of Directors since March...

Neutral

Cytokinetics, Incorporated Presents at Needham ...

2022-04-06 20:00:00

Cytokinetics, Incorporated Presents at Needham 21st Annual Healthcare Conference, Apr-13-2022 11:00 AM. Speakers: Robert I. Blum, CEO, Preside...

Positive

Cytokinetics Announces Results From METEORIC-HF...

2022-04-03 13:45:00

Cytokinetics, Incorporated announced that the full results from METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv MecarbilRe...

Positive

Cytokinetics Announces Results From Cohort 3 of...

2022-04-02 15:30:00

Cytokinetics, Incorporated announced that the full results from Cohort 3 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstru...

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Glo...

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami B...

Neutral

JMP Securities LLC, the JMP Securities Life Sci...

2022-02-16 16:45:00

JMP Securities LLC, The JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022. Venue: Lotte New York Palace, 455 Mad...

Neutral

Cytokinetics, Incorporated Presents at American...

2022-02-15 18:52:00

Cytokinetics, Incorporated Presents at American College of Cardiology Annual Scientific Session & Expo, Apr-01-2022 through Apr-04-2022. Venue...

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Neutral

Needham & Company, LLC, Needham 21st Annual Hea...

2022-02-11 23:04:00

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022.

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43...

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Reso...

Neutral

The Amyotrophic Lateral Sclerosis Association, ...

2022-02-07 17:12:00

The Amyotrophic Lateral Sclerosis Association, ALS Drug Development Summit, May 24, 2022 through May 26, 2022. Venue: Boston, United States.

Positive

Cytokinetics, Incorporated Announces FDA Accept...

2022-02-04 12:30:00

Cytokinetics, Incorporated announced that the U.S. Food & Drug Administration (FDA) has accepted and filed the company’s New Drug Application ...

Positive

Cytokinetics, Incorporated Announces Positive T...

2022-02-01 12:30:00

Cytokinetics, Incorporated announced positive topline results from Cohort 3 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obs...

Neutral

American College of Cardiology, Inc., American ...

2022-01-26 12:00:00

American College of Cardiology, Inc., American College of Cardiology Annual Scientific Session & Expo, Apr 01, 2022 through Apr 04, 2022. Venu...

Neutral

Cytokinetics and JI XING Announce Expansion of ...

2021-12-20 12:30:00

Cytokinetics, Incorporated and Ji Xing Pharmaceuticals Limited announced an expansion of their collaboration by entering into an exclusive lic...

Neutral

Cytokinetics Incorporated Enters into License a...

2021-12-20 12:30:00

On December 20, 2021, Cytokinetics, Incorporated entered into a License and Collaboration Agreement with Ji Xing Pharmaceuticals Limited, purs...

Neutral

Cytokinetics, Incorporated - Special Call

2021-12-20 09:14:00

Cytokinetics and JI XING Announce Expansion of Collaboration to Include Licensing of Omecamtiv Mecarbil in China; RTW to Add to Its Investment...

Positive

Cytokinetics, Incorporated announced that it ex...

2021-12-20 00:00:00

Cytokinetics, Incorporated announced that it has entered into common stock purchase agreements with each of RTW Master Fund, Ltd., RTW Innovat...

Positive

Cytokinetics, Incorporated Announces New Data P...

2021-12-10 12:30:00

Cytokinetics, Incorporated announced that new data were presented at the 32nd International Symposium on ALS/MND including an analysis of base...

Positive

Cytokinetics, Incorporated Announces Receipt of...

2021-12-09 12:30:00

Cytokinetics, Incorporated announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for aficamt...

Negative

Cytokinetics, Incorporated Announces That the U...

2021-12-09 12:30:00

Cytokinetics, Incorporated announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for aficamten for...

Neutral

Cytokinetics, Incorporated Presents at Piper Sa...

2021-11-22 15:06:00

Cytokinetics, Incorporated Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, Unite...

Neutral

Cytokinetics, Incorporated Presents at Piper Sa...

2021-11-19 21:08:00

Cytokinetics, Incorporated Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM.

Positive

Cytokinetics, Incorporated Announces Additional...

2021-11-15 12:30:00

Cytokinetics, Incorporated announced that additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Im...

Neutral

Cytokinetics, Incorporated Presents at 4th Annu...

2021-11-10 13:45:00

Cytokinetics, Incorporated Presents at 4th Annual ALS ONE Research Symposium, Nov-30-2021 02:00 PM.

Neutral

ALS One, 4th Annual ALS ONE Research Symposium,...

2021-11-10 13:00:00

ALS One, 4th Annual ALS ONE Research Symposium, Nov 29, 2021 through Nov 30, 2021.

Neutral

ALS One, 4th Annual ALS ONE Research Symposium,...

2021-11-10 13:00:00

ALS One, 4th Annual ALS ONE Research Symposium, Nov 29, 2021 through Nov 30, 2021.

Neutral

Cytokinetics, Incorporated has filed a Shelf Re...

2021-11-05 00:00:00

Cytokinetics, Incorporated has filed a Shelf Registration in the amount of $42.867 million. Security Name: Common Stock Securities Offered...

Positive

Cytokinetics Announces Preclinical Data Relatin...

2021-10-29 11:30:00

Cytokinetics, Incorporated announced that preclinical data relating to the discovery and optimization of CK-3828136 (CK-136) were presented at...

Neutral

Piper Sandler Companies, Piper Sandler 33rd Ann...

2021-10-25 10:00:00

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.

Neutral

Cytokinetics, Incorporated to Report Q3, 2021 R...

2021-10-20 20:00:00

Cytokinetics, Incorporated announced that they will report Q3, 2021 results at 4:00 PM, US Eastern Standard Time on Nov 03, 2021

Neutral

Cytokinetics, Incorporated, Q3 2021 Earnings Ca...

2021-10-20 20:00:00

Cytokinetics, Incorporated, Q3 2021 Earnings Call, Nov 03, 2021

Positive

Cytokinetics Outlines Go-To-Market Strategy for...

2021-10-07 11:30:00

Cytokinetics, Incorporated planed to outline the company’s go-to-market strategy for omecamtiv mecarbil in the United States, and present upda...

Neutral

Cytokinetics, Incorporated - Analyst/Investor Day

2021-09-23 20:00:00

To provide updates on the company’s plans for commercialization and advancing cardiovascular pipeline

Positive

Cytokinetics, Incorporated Announces Results fr...

2021-09-12 15:45:00

Cytokinetics, Incorporated announced that the full results from REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflo...

Neutral

Cytokinetics, Incorporated Presents at Cantor G...

2021-09-08 23:10:00

Cytokinetics, Incorporated Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 03:20 PM. Venue: New York, United States.

Neutral

Cytokinetics, Incorporated Presents at H.C. Wai...

2021-09-08 23:10:00

Cytokinetics, Incorporated Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 12:00 PM. Venue: Lotte New York P...

Neutral

Cytokinetics, Incorporated Presents at Morgan S...

2021-09-08 23:10:00

Cytokinetics, Incorporated Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-14-2021 11:45 AM. Venue: New Windsor, Unit...

Neutral

Cytokinetics, Incorporated - Special Call

2021-09-07 11:30:00

To discuss the full results from REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM)

Positive

Cytokinetics Announces Results From REDWOOD-HCM...

2021-08-31 11:30:00

Cytokinetics, Incorporated announced that the full results from REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflo...

Neutral

Cytokinetics, Incorporated Updates Its Financia...

2021-08-05 20:00:00

Cytokinetics, Incorporated updated its financial guidance for 2021. The company expects its revenues for 2021 will be in the range of $23 mill...

Positive

Cytokinetics, Incorporated Announces COURAGE-AL...

2021-08-02 11:30:00

On August 2, 2021, Cytokinetics, Incorporated announced that COURAGE-ALS is open to enrollment. Reldesemtiv, a next-generation fast skeletal m...

Neutral

Cytokinetics, Incorporated, Q2 2021 Earnings Ca...

2021-07-22 20:00:00

Cytokinetics, Incorporated, Q2 2021 Earnings Call, Aug 05, 2021

Neutral

Cytokinetics, Incorporated to Report Q2, 2021 R...

2021-07-22 20:00:00

Cytokinetics, Incorporated announced that they will report Q2, 2021 results at 4:00 PM, US Eastern Standard Time on Aug 05, 2021

Negative

Cytokinetics, Incorporated has completed a Foll...

2021-07-20 00:00:00

Cytokinetics, Incorporated has completed a Follow-on Equity Offering in the amount of $275 million. Security Name: Common Stock Security T...

Negative

Certain Common Stock of Cytokinetics, Incorpora...

2021-07-20 00:00:00

Certain Common Stock of Cytokinetics, Incorporated are subject to a Lock-Up Agreement Ending on 19-OCT-2021. These Common Stock will be under ...

Negative

Certain Warrants of Cytokinetics, Incorporated ...

2021-07-20 00:00:00

Certain Warrants of Cytokinetics, Incorporated are subject to a Lock-Up Agreement Ending on 19-OCT-2021. These Warrants will be under lockup f...

Negative

Certain Options of Cytokinetics, Incorporated a...

2021-07-20 00:00:00

Certain Options of Cytokinetics, Incorporated are subject to a Lock-Up Agreement Ending on 19-OCT-2021. These Options will be under lockup for...

Negative

Certain Restricted Stock Units of Cytokinetics,...

2021-07-20 00:00:00

Certain Restricted Stock Units of Cytokinetics, Incorporated are subject to a Lock-Up Agreement Ending on 19-OCT-2021. These Restricted Stock ...

Negative

Certain Performance Stock Units of Cytokinetics...

2021-07-20 00:00:00

Certain Performance Stock Units of Cytokinetics, Incorporated are subject to a Lock-Up Agreement Ending on 19-OCT-2021. These Performance Stoc...

Positive

Cytokinetics, Incorporated Announces Positive T...

2021-07-19 11:36:00

Cytokinetics, Incorporated announced positive topline results from Cohorts 1 and 2 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274...

Neutral

Cytokinetics, Incorporated - Special Call

2021-07-19 11:30:00

To discuss the results of REDWOOD-HCM

Negative

Cytokinetics, Incorporated has filed a Follow-o...

2021-07-19 00:00:00

Cytokinetics, Incorporated has filed a Follow-on Equity Offering in the amount of $200 million. Security Name: Common Stock Security Type:...

Positive

Cytokinetics, Incorporated Announces Additional...

2021-06-30 11:30:00

Cytokinetics, Incorporated announced that additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Im...

Positive

Cytokinetics, Incorporated Provides Update on New Drug Application

2022-06-17 11:36:00

On June 17, 2022, Cytokinetics, Incorporated announced that, in response to a request from the U.S. Food and Drug Administration (FDA), the company recently provided additional pharmacokinetic analyses of omecamtiv mecarbil related to the company’s new drug application (NDA). After an initial review of the company’s submission, on June 15, 2022, FDA communicated to the Company that the additional data provided constitutes a major amendment to the NDA and has extended the PDUFA date by three months to February 28, 2023 to provide time for a full review of the submission.

Positive

Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS

2022-06-16 11:30:00

Cytokinetics, Incorporated announced the start of COURAGE-ALS OLE (Clinical Outcomes Using Reldesemtiv on ALSFRS-R in a Global Evaluation in ALS Open Label Extension), an open-label extension clinical study designed to assess the long-term safety and tolerability of reldesemtiv in people with amyotrophic lateral sclerosis (ALS). Patients will be eligible for COURAGE-ALS OLE after completing their participation in COURAGE-ALS, the Phase 3 clinical trial of reldesemtiv, a next-generation fast skeletal muscle troponin activator (FSTA) for the potential treatment of ALS. COURAGE-ALS OLE: Clinical Study Design: COURAGE-ALS OLE is an open-label extension clinical study of reldesemtiv in people with ALS who have completed participation in COURAGE-ALS. Following enrollment in COURAGE-ALS OLE, participants will continue to receive 300 mg of reldesemtiv dosed orally twice daily for 48 weeks after which they may transition into the Managed Access Program. The primary endpoint is the incidence of adverse events. Secondary endpoints include the time to the first occurrence of respiratory insufficiency or death, time to the first hospitalization, combined assessment of change in ALSFRS-R total score, time to onset of respiratory insufficiency, and survival time, changes in ALSFRS-R total score, and the slope of changes in ALSFRS-R total score.

Positive

Cytokinetics, Incorporated Announces Additional Data from Redwood-HCM Presented At the American Society of Echocardiography 33Rd Annual Scientific Sessions

2022-06-13 11:30:00

Cytokinetics, Incorporated announced that additional data from a new analysis of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM) relating to the effect of treatment with aficamten on measures of cardiac structure and function were presented at the American Society of Echocardiography (ASE) 33rd Annual Scientific Sessions by Theodore Abraham, M.D., F.A.C.C., Meyer Friedman Distinguished Professor of Medicine, Clinical Chief of Cardiology; Director of Echocardiography, University of California, San Francisco. This new analysis investigated changes from baseline in echocardiographic measures of cardiac structure and function after 10 weeks of treatment with aficamten compared with placebo. At baseline, all patients (n=41) enrolled in Cohorts 1 and 2 of REDWOOD-HCM had severe left ventricular outflow tract (LVOT) obstruction, 88% had associated systolic anterior motion (SAM) of the mitral valve, and 90% had mitral regurgitation. SAM occurs when the mitral valve leaflet gets pushed against the interventricular septum during systole, resulting in obstruction of the LVOT and mitral regurgitation. Measures of cardiac structure, diastolic and mitral valve functionimproved at Week 10 in patients treated with aficamten. There was a significant reduction in left atrial volume index (p<0.01) and a trend towards a reduction in left ventricular hypertrophy (left ventricular mass index; p=0.06). Treatment with aficamten also resulted in improved ventricular relaxation and filling, as indicated by a reduction in lateral E/e’ (p<0.01) and an increase in lateral e’ (p<0.05). Additionally, treatment with aficamten improved mitral valve dynamics as noted by a reduction in the proportion of patients with SAM (placebo: 92.3% at baseline to 75.0% at Week 10; aficamten: 85.7% at baseline to 35.7% at Week 10; p=0.038 for comparison to placebo) and a trend towards a reduction in those with eccentric mitral regurgitation (placebo: 25.0% at baseline to 33.3% at Week 10; aficamten: 42.9% at baseline to 7.1% at Week 10; p=0.055 for comparison to placebo) at Week 10. Together, these data point to evidence of early signs of improved cardiac function and structure and improved mitral valve dynamics after a 10-week treatment period with aficamten.

Neutral

Cytokinetics, Incorporated Presents at 33rd annual scientific session, Jun-10-2022

2022-06-13 11:30:00

Cytokinetics, Incorporated Presents at 33rd annual scientific session, Jun-10-2022 .

Neutral

American Society Of Echocardiography Incorporated, 33rd annual scientific session, Jun 10, 2022 through Jun 13, 2022

2022-06-07 12:48:00

American Society Of Echocardiography Incorporated, 33rd annual scientific session, Jun 10, 2022 through Jun 13, 2022.

Neutral

Cytokinetics, Incorporated Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 03:00 PM

2022-06-02 20:00:00

Cytokinetics, Incorporated Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 03:00 PM. Venue: Lotte New York Palace, 455 Madison Ave., New York City, New York, United States. Speakers: Robert I. Blum, CEO, President & Director.

Neutral

Cytokinetics, Incorporated Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-13-2022 02:40 PM

2022-06-02 20:00:00

Cytokinetics, Incorporated Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-13-2022 02:40 PM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: Robert I. Blum, CEO, President & Director.

Neutral

Cytokinetics, Incorporated Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 10:00 AM

2022-06-02 20:00:00

Cytokinetics, Incorporated Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 10:00 AM. Venue: Marriott Marquis, New York City, New York, United States. Speakers: Robert I. Blum, CEO, President & Director.

Neutral

Cytokinetics, Incorporated has filed a Shelf Registration in the amount of $318.12826 million.

2022-05-31 00:00:00

Cytokinetics, Incorporated has filed a Shelf Registration in the amount of $318.12826 million. Security Name: Common Stock Securities Offered: 7,598,000 Transaction Features: ESOP Related Offering

Neutral

Cytokinetics, Incorporated Presents at ALS Drug Development Summit, May-24-2022 through May-26-2022

2022-05-30 11:39:00

Cytokinetics, Incorporated Presents at ALS Drug Development Summit, May-24-2022 through May-26-2022. Venue: Boston, United States. Presentation Date & Speakers: May-25-2022, Andrew A. Wolff, Senior VP and Senior Fellow, Clinical Research & Development, Stacy Rudnicki, Vice President, Clinical Research.

Neutral

Cytokinetics, Incorporated Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM

2022-05-17 20:00:00

Cytokinetics, Incorporated Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States. Speakers: Robert I. Blum, CEO, President & Director.

Neutral

Cytokinetics, Incorporated - Shareholder/Analyst Call

2022-05-03 20:00:00

AGM

Neutral

Cytokinetics, Incorporated, Q1 2022 Earnings Call, May 04, 2022

2022-04-20 20:00:00

Cytokinetics, Incorporated, Q1 2022 Earnings Call, May 04, 2022

Neutral

Cytokinetics, Incorporated to Report Q1, 2022 Results on May 04, 2022

2022-04-20 20:00:00

Cytokinetics, Incorporated announced that they will report Q1, 2022 results at 4:00 PM, US Eastern Standard Time on May 04, 2022

Negative

Cytokinetics, Incorporated Announces Retirement of Mark A. Schlossberg as Senior Vice President, Legal, General Counsel and Secretary, Effective May 13, 2022

2022-04-15 20:34:00

On April 12, 2022, Mark A. Schlossberg, Senior Vice President, Legal, General Counsel and Secretary of Cytokinetics, Incorporated, informed Cytokinetics that he would be retiring from the company effective May 13, 2022. Mr. Schlossberg's departure is on mutually good terms between the Company and himself.

Neutral

Cytokinetics, Incorporated, Annual General Meeting, May 10, 2022

2022-04-08 20:06:00

Cytokinetics, Incorporated, Annual General Meeting, May 10, 2022, at 10:00 Pacific Daylight. Location: at its headquarters, 350 Oyster Point Blvd. South San Francisco California United States Agenda: To elect the Board of Directors’ nominees, Muna Bhanji, Santo J. Costa, Esq., John T. Henderson, M.B., Ch.B., and B. Lynne Parshall, Esq., as Class III Directors, each to serve for a three-year term and until their successors are duly elected and qualified; to approve the amendment and restatement of the Amended and Restated 2004 Equity Incentive Plan to increase the number of authorized shares reserved for issuance under the Amended and Restated 2004 Equity Incentive Plan by an additional 5,998,000 shares of common stock; to ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2022; to approve, on an advisory basis, the compensation of named executive officers, as disclosed in the Proxy Statement accompanying this notice; and to transact such other business as may properly be brought before the meeting.

Negative

Cytokinetics, Incorporated Announces Changes to Board of Directors

2022-04-08 11:30:00

Cytokinetics, Incorporated announced changes to its Board of Directors. L. Patrick Gage, Ph.D., Chairman of the Board of Directors since March 2010, will resign from the Board effective April 8, 2022. Following Dr. Gage’s retirement, the Board has appointed John T. Henderson, M.B., Ch.B. as Chairman of the Board. Additionally, Robert A. Harrington, M.D., Arthur L. Bloomfield Professor and Chair, Department of Medicine, Stanford University, has been appointed to the company’s Board of Directors, also effective April 08, 2022. He previously served as Vice President, Research & Development in Europe, and later Japan, as well as Vice President, Medical for Pfizer’s Europe, U.S., and International Pharmaceuticals groups. Dr. Harrington is a cardiologist and the Arthur L. Bloomfield Professor of Medicine and Chair of the Department of Medicine at Stanford University. Dr. Harrington was previously the Richard Sean Stack, MD Distinguished Professor and the Director of the Duke Clinical Research Institute (DCRI) at Duke University.

Neutral

Cytokinetics, Incorporated Presents at Needham 21st Annual Healthcare Conference, Apr-13-2022 11:00 AM

2022-04-06 20:00:00

Cytokinetics, Incorporated Presents at Needham 21st Annual Healthcare Conference, Apr-13-2022 11:00 AM. Speakers: Robert I. Blum, CEO, President & Director.

Positive

Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American College of Cardiology 71st Annual Scientific Session

2022-04-03 13:45:00

Cytokinetics, Incorporated announced that the full results from METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv MecarbilRelated to Increased Contractility in Heart Failure), a Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF), were presented by Michael Felker, M.D., Professor of Medicine, Duke Clinical Research Institute, at the American College of Cardiology 71st Annual Scientific Session (ACC.22). Additional data from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) were also presented including a healthcare resource utilization analysis and an analysis of the effect of treatment with omecamtiv mecarbil in hospitalized patients compared to outpatients. METEORIC-HF evaluated the effect of treatment with omecamtiv mecarbil compared to placebo on exercise capacity as determined by cardiopulmonary exercise testing (CPET) following 20 weeks of treatment in patients with HFrEF receiving standard of care therapy. The trial enrolled 276 patients in 9 countries. At baseline, patients had an average left ventricular ejection fraction (LVEF) of 27% and an average peak oxygen uptake (pVO2) of 14.7 ml/kg/min; 79% were New York Heart Association (NYHA) Functional Class II. After 20 weeks of treatment, there was no change in pVO2 in patients treated with omecamtiv mecarbil versus placebo. Patients treated with omecamtiv mecarbil had an average change from baseline in pVO2 of -0.2 ml/kg/min compared to 0.2 ml/kg/min for patients on placebo (p=0.13). There was no beneficial effect observed in any of the secondary endpoints, including change in total workload during exercise, change in ventilatory efficiency and change in daily physical activity. Adverse events, including major cardiac events, were similar between the treatment arms, even with patients reaching peak exercise.

Positive

Cytokinetics Announces Results From Cohort 3 of Redwood-HCM Presented at American College of Cardiology 71st Annual Scientific Session

2022-04-02 15:30:00

Cytokinetics, Incorporated announced that the full results from Cohort 3 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), the Phase 2 clinical trial of aficamten in patients with obstructive hypertrophic cardiomyopathy (HCM), were presented in a Moderated Poster Session by Anjali T. Owens, M.D., Medical Director, Center for Inherited Cardiac Disease, Assistant Professor of Medicine, University of Pennsylvania, at the American College of Cardiology 71st Annual Scientific Session (ACC.22). Cohort 3 of REDWOOD-HCM enrolled thirteen patients with symptomatic obstructive HCM and a resting or post-Valsalva left ventricular outflow tract gradient (LVOT-G) of =50 mmHg whose background therapy included disopyramide and, in the majority (11 out of 13 patients), a beta-adrenergic blocker. These patients remained symptomatic despite use of disopyramide and represent a group of patients resistant to available medical therapies. All patients received up to three escalating doses of aficamten once daily (5, 10, 15 mg), titrated based on echocardiographic guidance. The doses of aficamten employed were the same as those used in Cohort 1 of REDWOOD-HCM. Overall treatment duration was 10 weeks with a 4-week follow up period after the last dose. All patients completed the study on treatment. Patients in Cohort 3 demonstrated a substantial reduction in the mean (± SD) resting LVOT-G (from 50 ± 25 at baseline to 24 ± 17 mmHg at Week 10) and Valsalva LVOT-G (from 78 ± 27 to 50 ± 25 mmHg). For the resting LVOT-G, the least square mean difference (± SE) for the change from baseline to Week 10 was -28 ± 3.2 mmHg (p < 0.0001) and for the Valsalva LVOT-G was -27 ± 5.9 mmHg (p = 0.0002). The relief of obstruction was accompanied by a modest reduction in left ventricular ejection fraction (LVEF) (from 74 ± 7% at baseline to 69 ± 7% at Week 10) (Figure 2). For LVEF, the least square mean difference (± SE) for the change from baseline to Week 10 was -4.8 ± 1.9% (p = 0.018). There were no patients who experienced a reduction in LVEF below the prespecified safety threshold of 50%.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.

Neutral

JMP Securities LLC, the JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022

2022-02-16 16:45:00

JMP Securities LLC, The JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022. Venue: Lotte New York Palace, 455 Madison Ave., New York City, New York, United States.

Neutral

Cytokinetics, Incorporated Presents at American College of Cardiology Annual Scientific Session & Expo, Apr-01-2022 through Apr-04-2022

2022-02-15 18:52:00

Cytokinetics, Incorporated Presents at American College of Cardiology Annual Scientific Session & Expo, Apr-01-2022 through Apr-04-2022. Venue: Washington, District Of Columbia, United States. Presentation Date & Speakers: Apr-02-2022, Anjali T Owens, Medical Director, Center for Inherited Cardiac Disease, Assistant Professor. Apr-03-2022, Michael Felker, Professor of Medicine, Duke Clinical Research Institute. Apr-04-2022, Kieran F Docherty, Clinical Lecturer, Institute of Cardiovascular and Medical Sciences,University of Glasgow, Nihar R Desai, MPH, Associate Professor of Medicine, Associate Chief, Cardiovascular Medicine,Yale School of Medicine, Center for Outcomes Research and Evaluation.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022

2022-02-11 23:04:00

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022.

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.

Neutral

The Amyotrophic Lateral Sclerosis Association, ALS Drug Development Summit, May 24, 2022 through May 26, 2022

2022-02-07 17:12:00

The Amyotrophic Lateral Sclerosis Association, ALS Drug Development Summit, May 24, 2022 through May 26, 2022. Venue: Boston, United States.

Positive

Cytokinetics, Incorporated Announces FDA Acceptance of New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure with Reduced Ejection Fraction

2022-02-04 12:30:00

Cytokinetics, Incorporated announced that the U.S. Food & Drug Administration (FDA) has accepted and filed the company’s New Drug Application (NDA) for omecamtiv mecarbil, an investigational, selective, small molecule cardiac myosin activator, for the treatment of heart failure with reduced ejection fraction (HFrEF). The FDA assigned the NDA a standard review with a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2022. The FDA also indicated that it is currently not planning to hold an advisory committee meeting to discuss the application. The NDA is supported by the results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 cardiovascular outcomes clinical trial of omecamtiv mecarbil that enrolled over 8,000 patients in 35 countries across 945 sites. GALACTIC-HF demonstrated a statistically significant effect of treatment with omecamtiv mecarbil to reduce risk of the primary composite endpoint of cardiovascular (CV) death or heart failure events (heart failure hospitalization and other urgent treatment for heart failure) compared to placebo in patients treated with standard of care. Additional analyses from GALACTIC-HF demonstrated a greater treatment effect of omecamtiv mecarbil in patients with lower left ventricular ejection fraction (LVEF), as well as other characteristics that may indicate worsening heart failure.

Positive

Cytokinetics, Incorporated Announces Positive Topline Results from Cohort 3 of REDWOOD-HCM

2022-02-01 12:30:00

Cytokinetics, Incorporated announced positive topline results from Cohort 3 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), the Phase 2 clinical trial of aficamten, an investigational next-generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic cardiomyopathy (HCM). Cohort 3 of REDWOOD-HCM enrolled patients with symptomatic obstructive HCM and a resting or post-Valsalva left ventricular outflow tract gradient (LVOT-G) of =50 mmHg whose background therapy included disopyramide and in the majority a beta-adrenergic blocker. All patients received up to three escalating doses of aficamten once daily (5, 10, 15 mg), titrated based on echocardiographic guidance. The doses employed were the same as those used in Cohort 1 of REDWOOD-HCM. Overall treatment duration was 10 weeks with a 4-week follow up period after the last dose. In total, thirteen patients were enrolled and all patients completed the study on treatment. Results from Cohort 3 showed that substantial reductions in the average resting LVOT-G as well as the post-Valsalva LVOT-G (defined as resting gradient <30 mmHg and post-Valsalva gradient <50 mmHg) were achieved. These clinically relevant decreases in pressure gradients were achieved with only modest decreases in average left ventricular ejection fraction (LVEF); there were no patients whose LVEF fell below the prespecified safety threshold of 50%. New York Heart Association functional class was improved in the majority of patients participating in Cohort 3 of the trial. Pharmacokinetic data were similar to those observed in Cohorts 1 and 2. In addition, the safety and tolerability of aficamten were consistent with prior experience in REDWOOD-HCM with no treatment interruptions and no serious adverse events attributed to treatment reported by the investigators. The results from Cohort 3 of REDWOOD-HCM have been accepted for presentation at the American College of Cardiology 71st Annual Scientific Session & Expo in Washington, DC in April.

Neutral

American College of Cardiology, Inc., American College of Cardiology Annual Scientific Session & Expo, Apr 01, 2022 through Apr 04, 2022

2022-01-26 12:00:00

American College of Cardiology, Inc., American College of Cardiology Annual Scientific Session & Expo, Apr 01, 2022 through Apr 04, 2022. Venue: Washington, District Of Columbia, United States.

Neutral

Cytokinetics and JI XING Announce Expansion of Collaboration to Include Licensing of Omecamtiv Mecarbil in China

2021-12-20 12:30:00

Cytokinetics, Incorporated and Ji Xing Pharmaceuticals Limited announced an expansion of their collaboration by entering into an exclusive license and collaboration agreement to develop and commercialize omecamtiv mecarbil for the proposed treatment of heart failure with reduced ejection fraction (HFrEF) in Greater China. In addition to the license and collaboration agreement with JI XING, Cytokinetics has also entered into Common Stock Purchase Agreements that provide for the sale and issuance to entities affiliated with RTW of 511,182 of shares of Cytokinetics common stock at a price per share of $39.125. Pursuant to these transactions, Cytokinetics will receive committed capital of $70 million, comprised of $50 million from JI XING of upfront and near-term payments under the collaboration agreement and $20 million from RTW as proceeds for the sale of common stock. In addition, Cytokinetics will be eligible to receive up to $330 million from JI XING in additional milestone payments plus tiered royalties on the net sales of omecamtiv mecarbil in Greater China, subject to certain reductions.

Neutral

Cytokinetics Incorporated Enters into License and Collaboration Agreement with Ji Xing Pharmaceuticals Limited

2021-12-20 12:30:00

On December 20, 2021, Cytokinetics, Incorporated entered into a License and Collaboration Agreement with Ji Xing Pharmaceuticals Limited, pursuant to which Cytokinetics granted to Ji Xing an exclusive license to develop and commercialize Cytokinetics’ proprietary small molecule cardiac sarcomere activator known as omecamtiv mecarbil (the “Product”) in the greater China region, namely mainland China, Hong Kong, Macau, and Taiwan. Under the terms of the License Agreement, Cytokinetics will receive from Ji Xing an upfront and near-term milestone payments of $50 million. Cytokinetics may be eligible to receive from Ji Xing additional milestone payments totaling up to $330 million for the achievement of certain commercial milestone events with respect to the Product. In addition, Ji Xing will pay to Cytokinetics tiered royalties from the mid-teens to the low twenties range on the net sales of the Product in the greater China region, subject to certain reductions for generic competition, patent expiration and payments for licenses to third-party patents. Ji Xing will be responsible for the development and commercialization of the Product in its territory at its own cost and is required to use diligent efforts to develop and commercialize the Product in the greater China region. The development of the Product will be initially focused on heart failure with reduced ejection fraction (HFrEF), and Ji Xing will have the opportunity to participate in future Cytokinetics’ global clinical trials of the Product. Cytokinetics will supply the Product to Ji Xing either as a finished product or as an active pharmaceutical ingredient. The License Agreement, unless terminated earlier, will continue on a market-by-market basis until expiration of the relevant royalty term. Ji Xing has the right to terminate the License Agreement for convenience. Each party may terminate the License Agreement for the other party’s uncured material breach, insolvency, or failure to perform due to extended force majeure events. Cytokinetics may also terminate the License Agreement if Ji Xing challenges Cytokinetics’ patents or undergoes certain change of control transactions. Product rights will revert to Cytokinetics upon termination, and, under certain circumstances, subject to a low single-digit royalty payments on the net sales of the Product in the greater China region.

Neutral

Cytokinetics, Incorporated - Special Call

2021-12-20 09:14:00

Cytokinetics and JI XING Announce Expansion of Collaboration to Include Licensing of Omecamtiv Mecarbil in China; RTW to Add to Its Investment in Cytokinetics

Positive

Cytokinetics, Incorporated announced that it expects to receive $19.999996 million in funding from RTW Investments, LP

2021-12-20 00:00:00

Cytokinetics, Incorporated announced that it has entered into common stock purchase agreements with each of RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., RTW Venture Fund Limited, funds managed by RTW Investments, LP for a private placement of 511,182 shares at a price of $39.125 per share for gross proceeds of $19,999,995.75 on December 20, 2021. The closing will occur on December 20, 2021. The Investors have agreed to certain trading and other restrictions with respect to the shares, including a restriction on sales or other transfers of the shares, subject to certain exceptions, for a period of one year from the closing date.

Positive

Cytokinetics, Incorporated Announces New Data Presented At the 32nd International Symposium on ALS/MND

2021-12-10 12:30:00

Cytokinetics, Incorporated announced that new data were presented at the 32nd International Symposium on ALS/MND including an analysis of baseline characteristics from the initial patients enrolled in COURAGE-ALS (Clinical Outcomes Using Reldesemtiv on ALSFRS-R in a Global Evaluation in ALS), the ongoing Phase 3 clinical trial of reldesemtiv in patients with amyotrophic lateral sclerosis (ALS). In addition, supplemental analyses from FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints – in ALS), the Phase 2 clinical trial of reldesemtiv in ALS were presented, as were results from the IMPACT ALS Europe survey, a patient and caregiver survey funded in part by Cytokinetics. COURAGE-ALS: Analysis of Baseline Characteristics for First 27 Patients Enrolled: Stacy Rudnicki, M.D., Vice President, Clinical Research, Cytokinetics presented an analysis of the baseline characteristics of the first 27 patients enrolled in COURAGE-ALS. COURAGE-ALS is a Phase 3, multi-center, double-blind, randomized, placebo-controlled trial of reldesemtiv expected to enroll approximately 555 patients with ALS. Analyses conducted post hoc from FORTITUDE-ALS, the completed Phase 2 clinical trial of reldesemtiv, suggested that treatment effects were more evident in patients with faster rates of disease progression. These findings informed the inclusion criteria for COURAGE-ALS with the aim of enrolling a higher proportion of patients with middle to fast disease progression. Key inclusion criteria in COURAGE-ALS include symptom onset within 24 months and ALS Functional Rating Scale-Revised (“ALSFRS-R”) total score of =44. COURAGE-ALS began enrolling patients in August 2021, and 27 patients had been enrolled at the time of this analysis. The disease progression rate of each patient prior to enrollment was estimated using a formula based on ALSFRS-R score at entry into the trial and duration of ALS symptoms; progression rates were categorized as slow (=0.37 points per month), middle (>0.37–0.67 points per month) and fast (>0.67 points per month). These categories were defined by equally dividing the disease progression rates of patients enrolled in FORTITUDE-ALS into tertiles. In COURAGE-ALS, the majority of the patients enrolled at the time of this analysis were middle progressors (48.2%) or fast progressors (37.0%). From this analysis it appears that adjusting the inclusion criteria in COURAGE-ALS is achieving the intended goal of increasing the proportion of patients with middle to fast disease progression rates, as compared to FORTITUDE-ALS. FORTITUDE-ALS: Grip Strength Correlated with Fine Motor Function and Arm Function: Andrew Wolff, M.D., Senior Vice President, Senior Fellow, Clinical Research and Development, Cytokinetics presented supplemental analyses from FORTITUDE-ALS evaluating the relationship between declining grip strength and motor function. In FORTITUDE-ALS, secondary and exploratory endpoints included change from baseline in the ALSFRS-R, in which higher scores represent better physical function, change from baseline in the ALS Assessment Questionnaire (“ALSAQ-5”), a patient reported measure of health status in which higher scores represent worse quality of life, and change from baseline in grip strength. Measurements for ALSFRS-R, ALSAQ-5, and bilateral grip strength were collected at Screening, Day 1, Weeks 2, 4, 8, 12 and Follow-up. For all seven time points collected, average grip strength was strongly correlated with the ALSFRS-R fine motor domain sub-score with an overall Spearman correlation coefficient of 0.723 (p<0.0001), indicating that declining grip strength was strongly correlated with decreasing ALSFRS-R fine motor domain sub-scores. Average grip strength was moderately inversely correlated with scores for Question 2 of the ALSAQ-5, which assesses the patients’ perception of difficulty using their arms and hands, with an overall Spearman correlation coefficient of -0.634 (p<0.0001), suggesting that declining grip strength was moderately correlated with increasing scores for Question 2 of the ALSAQ-5. These findings indicate that grip strength, which is frequently included as an outcome measure in ALS clinical trials and may be assessed as part of routine care for people with ALS, has clinical relevance due to its correlation to fine motor function and patient reported quality of life.

Positive

Cytokinetics, Incorporated Announces Receipt of Breakthrough Therapy Designation from FDA for Aficamten

2021-12-09 12:30:00

Cytokinetics, Incorporated announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is a next-generation cardiac myosin inhibitor in development for the potential treatment of HCM. Breakthrough Therapy Designation is granted by FDA to expedite the development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies on a clinically significant endpoint. A drug that receives Breakthrough Therapy Designation is eligible for all Fast Track designation features, intensive guidance on an efficient drug development program, and organizational commitment involving senior managers.

Negative

Cytokinetics, Incorporated Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Aficamten for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy

2021-12-09 12:30:00

Cytokinetics, Incorporated announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. Aficamten is a next-generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic cardiomyopathy. Breakthrough Therapy Designation is granted by FDA to expedite the development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies on a clinically significant endpoint. A drug that receives Breakthrough Therapy Designation is eligible for all Fast Track designation features, intensive guidance on an efficient drug development program, and organizational commitment involving senior managers.

Neutral

Cytokinetics, Incorporated Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021

2021-11-22 15:06:00

Cytokinetics, Incorporated Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Neutral

Cytokinetics, Incorporated Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM

2021-11-19 21:08:00

Cytokinetics, Incorporated Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM.

Positive

Cytokinetics, Incorporated Announces Additional Results from GALACTIC-HF Presented at American Heart Association Scientific Sessions 2021

2021-11-15 12:30:00

Cytokinetics, Incorporated announced that additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 clinical trial evaluating omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF), were presented by Dr. John Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, GALACTIC-HF, at the American Heart Association (AHA) Scientific Sessions 2021. Additional analyses presented from GALACTIC-HF focused on the effect of treatment with omecamtiv mecarbil on the risk of stroke in patients with heart failure with reduced ejection fraction (HFrEF). Among patients enrolled in the trial, 754 (9.2%) had a history of stroke. These patients were older, more likely to be non-white, and were more likely to have atrial fibrillation/flutter, hypertension, diabetes mellitus, ischemic heart disease, worse New York Heart Association (NYHA) functional class, and higher baseline NT-proBNP or troponin compared to patients with no history of stroke. A total of 194 non-fatal and fatal strokes were reported in GALACTIC-HF. Multivariate predictors of the incidence of first stroke in GALACTIC-HF included non-white race, history of stroke or percutaneous coronary intervention, and elevated baseline troponin or systolic blood pressure. The treatment effect of omecamtiv mecarbil on the primary composite endpoint of cardiovascular death or heart failure events was similar in patients with a history of stroke (hazard ratio 0.86; 95% confidence interval (CI) 0.70, 1.07; p=0.18) and in patients without a history of stroke (hazard ratio 0.93; 95% CI 0.87, 1.00; p=0.06; interaction p-value=0.40). However, among all patients who received omecamtiv mecarbil, the risk of first fatal or non-fatal stroke was reduced by 35% (hazard ratio 0.65; 95% CI 0.49, 0.87; p=0.004), and the risk of fatal stroke was reduced by 44% (hazard ratio 0.56; 95% CI 0.31, 0.99; p=0.048). Treatment with omecamtiv mecarbil was associated with greater reductions in stroke for patients with a history of stroke, reducing the risk by 77% (n=754, hazard ratio 0.23; 95% CI 0.09, 0.56; interaction p-value=0.001), as well as in patients with a history of atrial fibrillation, reducing the risk by 51% (n=3475, hazard ratio 0.49, CI 0.32, 0.76; p=0.001). Treatment with omecamtiv mecarbil also demonstrated a reduction in new onset atrial fibrillation/flutter (no atrial fibrillation/flutter present at screening: n=5987, hazard ratio 0.70, CI 0.50, 0.99; p=0.044; no history of atrial fibrillation/flutter: n=4757, hazard ratio 0.60, CI 0.37, 1.00; p=0.048). This reduction in stroke may be related to the reduction in adverse events of atrial fibrillation/flutter, as well as improvements in atrial and ventricular function that have been observed in GALACTIC-HF and previous clinical trials of omecamtiv mecarbil. These findings may have implications for the clinical impact of omecamtiv mecarbil and suggest that it has a potential added benefit of decreasing the risk of stroke in patients with HFrEF.

Neutral

Cytokinetics, Incorporated Presents at 4th Annual ALS ONE Research Symposium, Nov-30-2021 02:00 PM

2021-11-10 13:45:00

Cytokinetics, Incorporated Presents at 4th Annual ALS ONE Research Symposium, Nov-30-2021 02:00 PM.

Neutral

ALS One, 4th Annual ALS ONE Research Symposium, Nov 29, 2021 through Nov 30, 2021

2021-11-10 13:00:00

ALS One, 4th Annual ALS ONE Research Symposium, Nov 29, 2021 through Nov 30, 2021.

Neutral

ALS One, 4th Annual ALS ONE Research Symposium, Nov 29, 2021 through Nov 30, 2021

2021-11-10 13:00:00

ALS One, 4th Annual ALS ONE Research Symposium, Nov 29, 2021 through Nov 30, 2021.

Neutral

Cytokinetics, Incorporated has filed a Shelf Registration in the amount of $42.867 million.

2021-11-05 00:00:00

Cytokinetics, Incorporated has filed a Shelf Registration in the amount of $42.867 million. Security Name: Common Stock Securities Offered: 1,100,000 Transaction Features: ESOP Related Offering

Positive

Cytokinetics Announces Preclinical Data Relating to CK-3828136 Presented at the 2021 Medicinal Chemistry Gordon Research Conference

2021-10-29 11:30:00

Cytokinetics, Incorporated announced that preclinical data relating to the discovery and optimization of CK-3828136 (CK-136) were presented at the 2021 Medicinal Chemistry Gordon Research Conference in West Dover, VT. CK-136 is a novel, selective cardiac troponin activator in development for the potential treatment of diseases associated with impaired cardiac contractility, such as heart failure with reduced ejection fraction (HFrEF), right ventricular heart failure, and others. Data presented today describe the primary research objectives related to CK-136 including the identification of initial hit compounds and subsequent chemical optimization as well as preclinical characterization in biochemical assays, cardiac myocytes, and in vivo models of cardiac function. An initial cardiac troponin activator identified in screening was shown in a reconstituted sarcomere assay to selectively activate the cardiac troponin complex. Importantly, it did not inhibit phosphodiesterase 3 (PDE-3) IC50, and showed no effect on the cardiomyocyte calcium transient, indicating its selectivity. The optimization of the initial hit compound that led to CK-136 focused to maximizing the therapeutic window and its pharmacokinetic profile as could result in favorable increases in cardiac function. Preclinical studies demonstrated that the pharmacodynamic range for CK-136 was larger than that associated with omecamtiv mecarbil in similar preclinical models. Additionally, CK-136 demonstrated a pharmacokinetic profile and a projected human half-life that should enable once or twice daily dosing. These preclinical data suggest that CK-136 is a selective cardiac troponin activator with a favorable pharmacodynamic window associated with substantial increases in cardiac contractility, representing a potential approach to augmenting cardiac contractility in diseases characterized by reduced cardiac function.

Neutral

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021

2021-10-25 10:00:00

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.

Neutral

Cytokinetics, Incorporated to Report Q3, 2021 Results on Nov 03, 2021

2021-10-20 20:00:00

Cytokinetics, Incorporated announced that they will report Q3, 2021 results at 4:00 PM, US Eastern Standard Time on Nov 03, 2021

Neutral

Cytokinetics, Incorporated, Q3 2021 Earnings Call, Nov 03, 2021

2021-10-20 20:00:00

Cytokinetics, Incorporated, Q3 2021 Earnings Call, Nov 03, 2021

Positive

Cytokinetics Outlines Go-To-Market Strategy for Omecamtiv Mecarbil and Provides Updates on Cardiovascular Pipeline

2021-10-07 11:30:00

Cytokinetics, Incorporated planed to outline the company’s go-to-market strategy for omecamtiv mecarbil in the United States, and present updates on the company’s advancing cardiovascular pipeline and strategies to build a commercial franchise at “Charting the Commercial Course,” an Analyst and Investor Day in New York and live online. The company also plans to present the clinical trial design for SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM). THe company also presenting the design of SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM). SEQUOIA-HCM is a Phase 3 randomized, placebo-controlled, double-blind, multi-center clinical trial designed to evaluate aficamten in patients with symptomatic oHCM on background medical therapy for 24 weeks. The primary objective is to assess the effect of aficamten on change in peak oxygen uptake (pVO2) measured by cardiopulmonary exercise testing (CPET) from baseline to week 24. Secondary objectives include change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score from baseline to week 12 and week 24, the proportion of patients with =1 class improvement in New York Heart Association (NYHA) functional class from baseline to week 12 and week 24, change in post-Valsalva left ventricular outflow tract gradient (LVOT-G) to week 12 and week 24, the proportion of patients with post-Valsalva LVOT-G <30 mmHg, and change in total workload during CPET to week 24.

Neutral

Cytokinetics, Incorporated - Analyst/Investor Day

2021-09-23 20:00:00

To provide updates on the company’s plans for commercialization and advancing cardiovascular pipeline

Positive

Cytokinetics, Incorporated Announces Results from REDWOOD-HCM and GALACTIC-H

2021-09-12 15:45:00

Cytokinetics, Incorporated announced that the full results from REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), the Phase 2 clinical trial of aficamten in patients with hypertrophic cardiomyopathy (HCM), and additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) assessing the effect of omecamtiv mecarbil in Black patients with heart failure (HF) with reduced ejection fraction (HFrEF), were presented in a Late Breaking Clinical Trials session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Denver, CO, and virtually online. Marty Maron, M.D., Director, Hypertrophic Cardiomyopathy Center; Tufts University School of Medicine, and Principal Investigator of REDWOOD-HCM presented the primary results of REDWOOD-HCM. The baseline characteristics of patients in REDWOOD-HCM were consistent with a symptomatic patient population with high resting and Valsalva gradients reflective of substantial burden of disease. Treatment with aficamten for 10 weeks resulted in statistically significant reductions from baseline compared to placebo in the average resting left ventricular (LV) outflow tract pressure gradient (LVOT-G) (p=0.0003, p=0.0004, Cohort 1 and Cohort 2, respectively) and the average post-Valsalva LVOT-G (p=0.001, p<0.0001, Cohort 1 and Cohort 2, respectively). The majority of patients treated with aficamten (78.6% in Cohort 1 and 92.9% in Cohort 2) achieved the target goal of treatment, defined as resting gradient <30 mmHg and post-Valsalva gradient <50 mmHg at Week 10 compared to placebo (7.7%). Reductions in LVOT-G occurred within two weeks of initiating treatment with aficamten, were maximized within two to six weeks of the start of dose titration and were sustained until the end of treatment at 10 weeks. Reversibility of the pharmacodynamic effect of aficamten was seen after a two-week washout, with resting LVOT-G, post-Valsalva LVOT-G, NT-proBNP and LVEF returning to baseline values. The observed reductions in LVOT-G were dose dependent, with patients achieving greater reductions of LVOT-G with increasing doses of aficamten. Over the 10-week study period, patients treated with aficamten in both Cohort 1 and Cohort 2 also experienced statistically significant reductions in NT-proBNP (p=0.003). Treatment with aficamten was also associated with an improvement in heart failure functional class as measured by New York Heart Association (NYHA) class. Improvement by at least one class was achieved by 31% in the placebo group, 43% of patients in Cohort 1 (p>0.1) and 64% of patients in Cohort 2 (p=0.08).Treatment with aficamten in REDWOOD-HCM was generally well tolerated. Overall, the incidence of adverse events was similar between treatment arms, there were no treatment emergent adverse events that resulted in treatment interruption or discontinuation, and no serious adverse events ascribed to aficamten by investigators. All patients completed treatment per protocol. David E. Lanfear, M.D., FACC, Section Head, Advanced Heart Failure and Transplant Cardiology; Co-Director, Center for Individualized and Genomic Medicine Research, Henry Ford Hospital, presented additional analyses of the effects of omecamtiv mecarbil in Black patients enrolled in GALACTIC-HF. Of 8,256 patients enrolled in the trial, 562 were Black (6.8%) and 285 were randomized to receive treatment with omecamtiv mecarbil. Among Black patients, treatment with omecamtiv mecarbil resulted in a trend towards reduction in the primary endpoint by 18% (HR=0.82, 95% CI 0.64-1.04), corresponding to a reduction in the primary event rate of 7.7/100 patient-years with a number-needed-to-treat of 13 patients. This result, like the overall study results, was driven primarily by a reduction in HF hospitalizations (HR=0.80) and HF events (HR=0.82), with no effect on cardiovascular mortality (HR=1.03) (Figure 2). There were no significant differences in adverse events in Black patients between the groups treated with omecamtiv mecarbil and placebo. A great majority of Black patients in GALACTIC-HF (n=535, 95%) were enrolled in the United States (n=357), South Africa (n=78) and Brazil (n=100). Black patients enrolled in these countries were younger, more often female, had lower ejection fraction (EF), more often had hypertension and diabetes, and were less likely to have atrial arrhythmias or ischemic etiology compared to white patients (each p=0.001). An analysis of Black patients enrolled only in these three countries showed that, compared to white patients from the same countries, they had a statistically similar overall benefit from treatment with omecamtiv mecarbil (HR=0.83 vs. HR=0.88), with a numerically greater risk reduction in hospitalization (HR=0.81 vs. HR=0.90).

Neutral

Cytokinetics, Incorporated Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 03:20 PM

2021-09-08 23:10:00

Cytokinetics, Incorporated Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 03:20 PM. Venue: New York, United States.

Neutral

Cytokinetics, Incorporated Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 12:00 PM

2021-09-08 23:10:00

Cytokinetics, Incorporated Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 12:00 PM. Venue: Lotte New York Palace Hotel, New York City, New York, United States.

Neutral

Cytokinetics, Incorporated Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-14-2021 11:45 AM

2021-09-08 23:10:00

Cytokinetics, Incorporated Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-14-2021 11:45 AM. Venue: New Windsor, United States.

Neutral

Cytokinetics, Incorporated - Special Call

2021-09-07 11:30:00

To discuss the full results from REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM)

Positive

Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF to Be Presented in Late Breaking Clinical Trials Session at the HFSA Annual Scientific Meeting

2021-08-31 11:30:00

Cytokinetics, Incorporated announced that the full results from REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), the Phase 2 clinical trial of aficamten in patients with hypertrophic cardiomyopathy (HCM), and additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) assessing the effect of omecamtiv mecarbil on Black patients with heart failure with reduced ejection fraction (HFrEF), have each been accepted for presentation in a Late Breaking Clinical Trials session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, taking place in Denver, CO, and virtually online from September 10-13, 2021.

Neutral

Cytokinetics, Incorporated Updates Its Financial Guidance for 2021

2021-08-05 20:00:00

Cytokinetics, Incorporated updated its financial guidance for 2021. The company expects its revenues for 2021 will be in the range of $23 million to $28 million and operating expenses will be in the range of $230 million to $250 million.

Positive

Cytokinetics, Incorporated Announces COURAGE-ALS Is Open to Enrollment

2021-08-02 11:30:00

On August 2, 2021, Cytokinetics, Incorporated announced that COURAGE-ALS is open to enrollment. Reldesemtiv, a next-generation fast skeletal muscle troponin activator (FSTA) arising from Cytokinetics’ skeletal muscle contractility program, slows the rate of calcium release from the regulatory troponin complex of fast skeletal muscle fibers, which sensitizes the sarcomere to calcium, leading to an increase in skeletal muscle contractility. COURAGE-ALS follows FORTITUDE-ALS, a Phase 2 clinical trial of reldesemtiv that demonstrated encouraging results supportive of progression to a pivotal Phase 3 clinical trial. COURAGE-ALS: Clinical Trial Design Focused on Innovation and Accessibility: COURAGE-ALS, a Phase 3, multi-center, double-blind, randomized, placebo-controlled trial of reldesemtiv is expected to enroll approximately 555 patients with ALS. Patients will be randomized 2:1 to receive 300 mg of reldesemtiv or matching placebo dosed orally twice daily for 24 weeks, followed by a 24-week period in which all patients will receive 300 mg of reldesemtiv twice daily. Eligible patients will be within the first two years of their first symptom of muscle weakness, have a vital capacity of =65% predicted, and a screening ALS Functional Rating Scale – Revised (ALSFRS-R) =44. Patients currently taking stable doses of Radicava® (edaravone) and/or Rilutek® (riluzole) will be permitted and randomization stratified accordingly. The primary efficacy endpoint will be change from baseline to 24 weeks in ALSFRS-R. Secondary endpoints include combined assessment of ALSFRS-R total score, time to onset of respiratory insufficiency and survival time up to week 24 using a joint rank test; change from baseline to 24 weeks for vital capacity; ALSAQ-40; and bilateral handgrip strength. Two unblinded interim analyses by the Data Monitoring Committee are planned. The first interim analysis will assess for futility, 12 weeks after approximately one-third or more of the planned sample size is randomized. A second interim analysis will also assess for futility, and there will be an option for a fixed increase in total enrollment, if necessary, to augment the statistical power of the trial. COURAGE-ALS: Elevating Patient Voice: Cytokinetics has established an ALS Patient and Caregiver Advisory Council (ALS-PAC) to elevate the voices of patients and caregivers into everything we do from planning and execution of clinical trial programs to educational materials related to the disease and our potential new therapies. Based on feedback from the ALS-PAC as well as a series of meetings with patients, caregivers, advocates, payors and healthcare professionals, the design of COURAGE-ALS incorporates elements designed to remove barriers to clinical trial participation including remote clinic visits, home nursing visits, and mobile-app based endpoint measurements. Additionally, at least one patient representative will serve on the steering committee of COURAGE-ALS to provide patient perspective on the continuing conduct of the trial and interpretation of results. The company is planning to provide continued access to reldesemtiv for participants who complete COURAGE-ALS, as well as for those who participated in our prior ALS trials. The access program will be developed with the objective to ensure safe, ethical and equitable access to reldesemtiv. FORTITUDE-ALS: Clinical Trial Design and Results: FORTITUDE-ALS was a Phase 2, double-blind, randomized, dose-ranging, placebo-controlled, parallel group study of reldesemtiv in patients with ALS. 458 eligible ALS patients from centers in the U.S., Canada, Europe and Australia were randomized (1:1:1:1) to receive either 150 mg, 300 mg or 450 mg of reldesemtiv or placebo dosed orally twice daily for 12 weeks. The primary efficacy endpoint was the change from baseline in the percent predicted SVC, a measure of respiratory function, at 12 weeks. Secondary endpoints included change from baseline in the ALS Functional Rating Scale – Revised (ALSFRS-R) and slope of the change from baseline in the mega-score of muscle strength measured by hand held dynamometry and handgrip dynamometry in patients on reldesemtiv; incidence and severity of treatment-emergent adverse events (TEAEs); and plasma concentrations of reldesemtiv at the sampled time points during the clinical trial. FORTITUDE-ALS did not achieve statistical significance for a pre-specified dose-response relationship in its primary endpoint of change from baseline in slow vital capacity (SVC) after 12 weeks of dosing (p=0.11). Similar analyses of ALSFRS-R and slope of the Muscle Strength Mega-Score yielded p-values of 0.09 and 0.31, respectively. However, patients on all dose groups of reldesemtiv declined less than patients on placebo for SVC and ALSFRS-R, with larger and clinically meaningful differences emerging over time. While the dose-response analyses for the primary and secondary endpoints did not achieve statistical significance at the level of 0.05, in a post-hoc analysis pooling the doses together, patients who received reldesemtiv in FORTITUDE-ALS declined less than patients who received placebo. The trial showed effects favoring reldesemtiv across dose levels and timepoints with clinically meaningful magnitudes of effect observed at 12 weeks for the primary and secondary endpoints. The differences between reldesemtiv and placebo in SVC and ALSFRS-R total score observed after 12 weeks of treatment were still evident at follow-up, four weeks after the last dose of study drug. The incidence of early treatment discontinuations, serious adverse events and clinical adverse events in FORTITUDE-ALS were similar between placebo and active treatment arms.

Neutral

Cytokinetics, Incorporated, Q2 2021 Earnings Call, Aug 05, 2021

2021-07-22 20:00:00

Cytokinetics, Incorporated, Q2 2021 Earnings Call, Aug 05, 2021

Neutral

Cytokinetics, Incorporated to Report Q2, 2021 Results on Aug 05, 2021

2021-07-22 20:00:00

Cytokinetics, Incorporated announced that they will report Q2, 2021 results at 4:00 PM, US Eastern Standard Time on Aug 05, 2021

Negative

Cytokinetics, Incorporated has completed a Follow-on Equity Offering in the amount of $275 million.

2021-07-20 00:00:00

Cytokinetics, Incorporated has completed a Follow-on Equity Offering in the amount of $275 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: $27.5 Discount Per Security: $1.65

Negative

Certain Common Stock of Cytokinetics, Incorporated are subject to a Lock-Up Agreement Ending on 19-OCT-2021.

2021-07-20 00:00:00

Certain Common Stock of Cytokinetics, Incorporated are subject to a Lock-Up Agreement Ending on 19-OCT-2021. These Common Stock will be under lockup for 91 days starting from 20-JUL-2021 to 19-OCT-2021. Details: The directors and executive officers have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each lock-up party, with limited exceptions, for a period of 90 days after the date of this prospectus, may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, offer, sell, assign, transfer, lend, pledge, contract to sell, or otherwise dispose of, or announce the intention to otherwise dispose of, any shares of its common stock or any securities convertible into or exercisable or exchangeable for its common stock (including, without limitation, common stock or such other securities which may be deemed to be beneficially owned by such lock-up parties in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant (collectively with the common stock, the “lock-up securities”)), enter into any swap, hedge or similar agreement or arrangement that transfers in whole or in part the economic risk of ownership of the lock-up securities, or engage in any short selling of its common stock or securities convertible into or exercisable or exchangeable for its common stock.

Negative

Certain Warrants of Cytokinetics, Incorporated are subject to a Lock-Up Agreement Ending on 19-OCT-2021.

2021-07-20 00:00:00

Certain Warrants of Cytokinetics, Incorporated are subject to a Lock-Up Agreement Ending on 19-OCT-2021. These Warrants will be under lockup for 91 days starting from 20-JUL-2021 to 19-OCT-2021. Details: The directors and executive officers have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each lock-up party, with limited exceptions, for a period of 90 days after the date of this prospectus, may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, offer, sell, assign, transfer, lend, pledge, contract to sell, or otherwise dispose of, or announce the intention to otherwise dispose of, any shares of its common stock or any securities convertible into or exercisable or exchangeable for its common stock (including, without limitation, common stock or such other securities which may be deemed to be beneficially owned by such lock-up parties in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant (collectively with the common stock, the “lock-up securities”)), enter into any swap, hedge or similar agreement or arrangement that transfers in whole or in part the economic risk of ownership of the lock-up securities, or engage in any short selling of its common stock or securities convertible into or exercisable or exchangeable for its common stock.

Negative

Certain Options of Cytokinetics, Incorporated are subject to a Lock-Up Agreement Ending on 19-OCT-2021.

2021-07-20 00:00:00

Certain Options of Cytokinetics, Incorporated are subject to a Lock-Up Agreement Ending on 19-OCT-2021. These Options will be under lockup for 91 days starting from 20-JUL-2021 to 19-OCT-2021. Details: The directors and executive officers have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each lock-up party, with limited exceptions, for a period of 90 days after the date of this prospectus, may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, offer, sell, assign, transfer, lend, pledge, contract to sell, or otherwise dispose of, or announce the intention to otherwise dispose of, any shares of its common stock or any securities convertible into or exercisable or exchangeable for its common stock (including, without limitation, common stock or such other securities which may be deemed to be beneficially owned by such lock-up parties in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant (collectively with the common stock, the “lock-up securities”)), enter into any swap, hedge or similar agreement or arrangement that transfers in whole or in part the economic risk of ownership of the lock-up securities, or engage in any short selling of its common stock or securities convertible into or exercisable or exchangeable for its common stock.

Negative

Certain Restricted Stock Units of Cytokinetics, Incorporated are subject to a Lock-Up Agreement Ending on 19-OCT-2021.

2021-07-20 00:00:00

Certain Restricted Stock Units of Cytokinetics, Incorporated are subject to a Lock-Up Agreement Ending on 19-OCT-2021. These Restricted Stock Units will be under lockup for 91 days starting from 20-JUL-2021 to 19-OCT-2021. Details: The directors and executive officers have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each lock-up party, with limited exceptions, for a period of 90 days after the date of this prospectus, may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, offer, sell, assign, transfer, lend, pledge, contract to sell, or otherwise dispose of, or announce the intention to otherwise dispose of, any shares of its common stock or any securities convertible into or exercisable or exchangeable for its common stock (including, without limitation, common stock or such other securities which may be deemed to be beneficially owned by such lock-up parties in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant (collectively with the common stock, the “lock-up securities”)), enter into any swap, hedge or similar agreement or arrangement that transfers in whole or in part the economic risk of ownership of the lock-up securities, or engage in any short selling of its common stock or securities convertible into or exercisable or exchangeable for its common stock.

Negative

Certain Performance Stock Units of Cytokinetics, Incorporated are subject to a Lock-Up Agreement Ending on 19-OCT-2021.

2021-07-20 00:00:00

Certain Performance Stock Units of Cytokinetics, Incorporated are subject to a Lock-Up Agreement Ending on 19-OCT-2021. These Performance Stock Units will be under lockup for 91 days starting from 20-JUL-2021 to 19-OCT-2021. Details: The directors and executive officers have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each lock-up party, with limited exceptions, for a period of 90 days after the date of this prospectus, may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, offer, sell, assign, transfer, lend, pledge, contract to sell, or otherwise dispose of, or announce the intention to otherwise dispose of, any shares of its common stock or any securities convertible into or exercisable or exchangeable for its common stock (including, without limitation, common stock or such other securities which may be deemed to be beneficially owned by such lock-up parties in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant (collectively with the common stock, the “lock-up securities”)), enter into any swap, hedge or similar agreement or arrangement that transfers in whole or in part the economic risk of ownership of the lock-up securities, or engage in any short selling of its common stock or securities convertible into or exercisable or exchangeable for its common stock.

Positive

Cytokinetics, Incorporated Announces Positive Topline Results from Cohorts 1 and 2 of REDWOOD-HCM

2021-07-19 11:36:00

Cytokinetics, Incorporated announced positive topline results from Cohorts 1 and 2 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), the Phase 2 clinical trial of CK-3773274 (CK-274), an investigational next-generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic cardiomyopathy (HCM). The results of REDWOOD-HCM inform dose selection and support progression of CK-274 to a planned Phase 3 registrational clinical trial which is expected to start before year end. Results from Cohorts 1 and 2 of REDWOOD-HCM demonstrated that treatment with CK-274 for 10 weeks resulted in statistically significant reductions from baseline compared to placebo in the average resting left ventricular outflow tract pressure gradient (LVOT-G) (p=0.0003, p=0.0004, Cohort 1 and Cohort 2, respectively) and the average post-Valsalva LVOT-G (p=0.001, p<0.0001, Cohort 1 and Cohort 2, respectively). The majority of patients treated with CK-274 (78.6% in Cohort 1 and 92.9% in Cohort 2) achieved the target goal of treatment, defined as resting gradient <30 mmHg and post-Valsalva gradient <50 mmHg at Week 10 compared to placebo (7.7%). Reductions in LVOT-G occurred within two weeks of initiating treatment with CK-274, were maximized within two to six weeks of the start of dose titration, and were sustained until the end of treatment at 10 weeks. The observed reductions in LVOT-G were dose dependent, with patients achieving greater reductions of LVOT-G with increasing doses of CK-274. Treatment with CK-274 in REDWOOD-HCM was generally well tolerated. The incidence of adverse events was similar between treatment arms. No serious adverse events were attributed to CK-274 and no treatment interruptions occurred on CK-274. No new cases of atrial fibrillation in patients treated with CK-274 were reported. In this dose-range finding trial, one patient experienced a transient decrease in left ventricular ejection fraction (LVEF) that required dose adjustment but not dose interruption. LVEF returned to baseline within two weeks after the end of treatment in both cohorts, which was consistent with the reversibility of LVEF decreases that were similarly observed in healthy participants in the Phase 1 study of CK-274. REDWOOD-HCM is a multi-center, randomized, placebo-controlled, double-blind, dose finding clinical trial of CK-274 in patients with symptomatic obstructive HCM (oHCM) on background medical therapy. The primary objective of the trial is to determine the safety and tolerability of CK-274. The secondary objectives are to describe the concentration-response relationship of CK-274 on the resting and post-Valsalva left ventricular outflow tract gradient as measured by echocardiography during 10 weeks of treatment, to describe the dose response relationship of CK-274, and to evaluate the plasma concentrations of CK-274 in patients with oHCM. Seventeen investigative sites in North America and Europe screened for patients to enroll in Cohort 1 and 2 of REDWOOD-HCM. Topline results from REDWOOD-HCM include data from two sequentially conducted cohorts, Cohort 1 (n=21) and Cohort 2 (n=20) which randomized treatment of patients 2:1 to CK-274 or placebo. Patients received up to three escalating doses of CK-274 once daily (5, 10, 15 mg in Cohort 1 and 10, 20, 30 mg in Cohort 2) or placebo. Patients had an echocardiogram after two weeks of treatment at each dose to determine potential up-titration to the next higher dose. Overall, treatment duration for each patient in REDWOOD-HCM was 10 weeks with an echocardiogram conducted 2 weeks after the last dose. For patients on CK-274 in Cohort 1 (n=14), the average resting LVOT-G changed from 53.8 mmHg at baseline to 13.4 mmHg at 10 weeks; for patients on CK-274 in Cohort 2 (n=14) the average resting LVOT-G changed from 58.2 mmHg at baseline to 15.1 mmHg at 10 weeks; and for patients in the combined placebo group (n=13) the average resting LVOT-G changed from 52.1 at baseline to 44.0 mmHg at 10 weeks (Figure 1, p=0.0003 for Cohort 1, p=0.0004 for Cohort 2 in comparison to placebo at 10 weeks). For patients on CK-274 in Cohort 1 (n=14) the average Valsalva LVOT-G changed from 74.4 mmHg at baseline to 38.1 mmHg at 10 weeks; for patients on CK-274 in Cohort 2 (n=14) the average Valsalva LVOT-G changed from 82.3 mmHg at baseline to 29.8 mmHg at 10 weeks; and for patients in the combined placebo group (n=13) the average Valsalva LVOT-G changed from 84.6 at baseline to 76.0 mmHg at 10 weeks (Figure 2; p=0.001 for Cohort 1, p<0.0001 for Cohort 2 in comparison to placebo at 10 weeks). The average ejection fraction for patients on CK-274 in Cohort 1 (n=14) changed from 73.2% at baseline to 67.4% at 10 weeks; for patients on CK-274 in Cohort 2 (n=14) the average ejection fraction changed from 75.4% at baseline to 64.1% at 10 weeks, and for patients in the combined placebo group (n=13) the average ejection fraction changed from 74.5% at baseline to 74.9% at 10 weeks (p=0.007 for Cohort 1, p=<0.0001 for Cohort 2 in comparison to placebo at 10 weeks). Overall, the incidence of adverse events was similar between treatment arms. Treatment with CK-274 in REDWOOD-HCM was generally well tolerated in patients being treated with current standard of care with adverse events reported as mild or moderate in severity. There were no treatment related serious adverse events reported by investigators. No patients who received CK-274 in Cohort 1 had an LVEF <50%. In Cohort 2, one patient with an LVEF at baseline of 58% was up-titrated to 20 mg of CK-274 and experienced transient LVEF reduction to <50% (remaining above 40%) requiring down titration. No interruptions or discontinuations of treatment with CK-274 occurred in any patients across both cohorts. The distribution (Table 1) of patients across doses of CK-274 in REDWOOD-HCM informs dose selection for the planned Phase 3 trial with the objective to assess clinical outcomes at the lowest effective individualized dose of CK-274.

Neutral

Cytokinetics, Incorporated - Special Call

2021-07-19 11:30:00

To discuss the results of REDWOOD-HCM

Negative

Cytokinetics, Incorporated has filed a Follow-on Equity Offering in the amount of $200 million.

2021-07-19 00:00:00

Cytokinetics, Incorporated has filed a Follow-on Equity Offering in the amount of $200 million. Security Name: Common Stock Security Type: Common Stock

Positive

Cytokinetics, Incorporated Announces Additional Results From GALACTIC-HF Presented at the European Society of Cardiology Heart Failure 2021

2021-06-30 11:30:00

Cytokinetics, Incorporated announced that additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) were presented at Heart Failure 2021, an International Congress of the European Society of Cardiology, including a prespecified subgroup analysis of the influence of atrial fibrillation or flutter (AFF) on the treatment effect of omecamtiv mecarbil in a Late Breaking Clinical Trial Session. Other analyses were presented in the Clinical Trial Updates Session related to which patients in GALACTIC-HF achieved an increased treatment effect with omecamtiv mecarbil. GALACTIC-HF: Patients Without Atrial Fibrillation or Flutter Have Increased Treatment Effect with Omecamtiv Mecarbil: Scott Solomon, M.D., the Edward D. Frohlich Distinguished Chair, Professor of Medicine, Harvard Medical School and Director of Noninvasive Cardiology, Brigham and Women's Hospital, presented additional analyses from GALACTIC-HF assessing how baseline AFF in patients impacted the effectiveness of omecamtiv mecarbil in GALACTIC-HF. Of the 8,256 patients enrolled in GALACTIC-HF, 2,245 patients (27%) had AFF at baseline; these patients were older, more likely to be randomized as inpatients, had a higher New York Heart Association (NYHA) class and had higher NT-proBNP compared to patients without AFF. The effect of treatment with omecamtiv mecarbil on the primary composite endpoint of heart failure events (heart failure hospitalization and other urgent treatment for heart failure) or cardiovascular (CV) death was greater in patients without baseline AFF compared to those patients with AFF at baseline (interaction p=0.012). Importantly, the modification of the treatment effect by AFF was concentrated in patients with AFF using digoxin (n=692) with minimal evidence of effect modification in patients with AFF not using digoxin (n=1553). Digoxin did not modify the treatment effect of omecamtiv mecarbil in patients without AFF. These findings suggest caution should be exercised when treating patients with AFF using both digoxin and omecamtiv mecarbil. Interestingly, given prior observations of the positive impact of omecamtiv mecarbil on left atrial function, an exploratory analysis from GALACTIC-HF indicated fewer serious adverse events of atrial fibrillation in patients without AFF at baseline in patients treated with omecamtiv mecarbil compared to placebo (55 events in 2,974 patients treated with omecamtiv mecarbil vs. 78 events in 3,013 patients treated with placebo, p=0.046). GALACTIC-HF: Patients with Higher Baseline NT-proBNP Have Increased Treatment Effect with Omecamtiv Mecarbil: In a separate analysis, John McMurray, M.D., Professor of Medical Cardiology & Honorary Consultant Cardiologist, Institute of Cardiovascular & Medical Sciences, BHF Cardiovascular Research Centre, University of Glasgow, presented analyses on the effect of treatment with omecamtiv mecarbil according to baseline NT-proBNP in patients without AFF, as well as in all patients in GALACTIC-HF. NT-proBNP is a biomarker of ventricular wall stress in which higher levels reflect more severe heart failure. Among the 5,971 patients who did not have AFF, the median (Q1, Q3) NT-proBNP level was 1,675 (812-3579 pg/ml). In patients without AFF, the treatment effect of omecamtiv mecarbil on the primary composite endpoint was increased in patients with a baseline NT-proBNP above the median (hazard ratio, 0.81; 95% confidence interval 0.73-0.90) compared to patients with baseline NT-proBNP equal to or below the median (HR, 0.94; 95% CI 0.80-1.09; interaction p=0.095). The same pattern was observed in the overall population in which patients with a baseline NT-proBNP greater than the median experienced an increased treatment effect (HR, 0.88; 95% CI 0.80-0.96) compared to patients with a baseline NT-proBNP equal to or below the median (HR, 1.01; 95% CI 0.90-1.15; interaction p=0.035.) Examined as a continuous variable, there was an interaction between treatment with omecamtiv mecarbil and baseline NT-proBNP that showed an increased treatment effect on the primary outcome in patients as baseline NT-proBNP increased both in those without AFF (interaction p=0.024) and in the overall population (interaction p=0.005). These findings suggest the benefit of treatment with omecamtiv mecarbil increased progressively as baseline NT-proBNP increased consistent with other analyses from GALACTIC-HF that suggest more severe heart failure patients may derive increased benefit from treatment with omecamtiv mecarbil. GALACTIC-HF: Patients with Severe Heart Failure Have Increased Treatment Effect with Omecamtiv Mecarbil: Michael Felker, M.D., Professor of Medicine, Duke Clinical Research Institute presented an analysis of the treatment effect of omecamtiv mecarbil on the primary composite endpoint in patients from GALACTIC-HF classified as having severe heart failure based on modified criteria from the Heart Failure Association of the European Society of Cardiology (ESC-HFA) advanced heart failure position statement. Patients in this subgroup had NYHA class III-IV symptoms, EF = 30%, and hospitalization for heart failure within the prior six months. Of patients enrolled in GALACTIC-HF, 2,258 (27%) met these criteria for severe heart failure. Patients with severe heart failure had markers of more advanced disease and higher baseline risk, with event rates in patients treated with placebo that were approximately twice those of patients without severe heart failure. In patients with severe heart failure, the treatment effect of omecamtiv mecarbil on the primary composite endpoint was increased (HR, 0.80; 95% CI 0.71-0.90) compared to patients without severe heart failure (HR, 0.99; 95% CI 0.91-1.08; interaction p=0.005). The results for CV death were qualitatively similar; patients with severe heart failure experienced a trend towards treatment benefit from omecamtiv mecarbil (HR, 0.88; 95% CI 0.75-1.03) while patients without severe heart failure did not (HR, 1.10, 95% CI 0.97-1.25; interaction p=0.028). Furthermore, as the severity of heart failure increased, as indicated by the number of the three severity criteria met, both the incidence of the primary composite endpoint and the treatment effect of omecamtiv mecarbil increased. Omecamtiv mecarbil was equally well tolerated in patients with and without severe heart failure, with no significant changes in blood pressure, renal function, or potassium compared to placebo. These results from GALACTIC-HF demonstrate a potentially clinically important treatment effect of omecamtiv mecarbil in patients with severe heart failure.

Fundamental Summary

Cytokinetics's recently released results from Q1 indicate that Cytokinetics is performing reasonably well and on par with its peers. This typically translates into the stock performing on par with market performance for the upcoming quarter. Therefore, they earned a total score of 65 out of 100 and a HOLD recommendation.

Cytokinetics reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 1.15 million compared to USD 6.55 million a year ago. Net loss was USD 89.45 million compared to USD 47.1 million a year ago. Basic loss per share from continuing operations was USD 1.05 compared to USD 0.66 a year ago.

Business Description

Cytokinetics, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Sector Overview

Cytokinetics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Cytokinetics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 856.3 1.8% 79
Liabilities 740.0 23.9% 49
Price to Book 29.9 88.5% 62
Cash & Equivalents 115.4 2.4% 76
Equity 116.3 -52.3% 42
EBITDA -193.1 -20.0% 50
Total Revenues 65.0 -7.7% 95
Parameter Value Change Score
Return on Equity -279.9 -132.2% 73
Net Cashflow 70.8 138.6% 63
Capital Expenditure -43.2 11.6% 89
Asset Turnover 0.1 -11.4% 51
Free Cashflow -2.3 8.5% 79

* All values are TTM

The below chart reflects Cytokinetics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Cytokinetics's peer average final assessment score stands on 64.0, Cytokinetics's score is 65.

  •  CYTK
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 3 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 4 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 5 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 7 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 8 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 9 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 10 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 11 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 12 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 13 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 15 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 16 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 17 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 18 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 19 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 21 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 22 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 23 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 25 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 27 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 29 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 30 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 31 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 32 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 35 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 36 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 37 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 38 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 39 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 40 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 41 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 42 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 43 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 45 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 46 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Cytokinetics's stock is now priced above its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the near, medium, and long-term. In particular, many institutional investors keep close watch of the 200-day moving average. The company is trading near it's 12-month high, which signals an attack on the resistance price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Cytokinetics's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators signal positive upward momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 78.

Bullish 78
Close Price 47.3
52W Low 18.54
52W High 48.92
5D MA 46.78
50D MA 39.99
200D MA 37.75
MACD 1.96
RSI 45.85
STOCH 83.93

Balance Sheet Analysis

Two main balance sheet metrics are driving the positive outlook for Cytokinetics's financial strength going forward. The company's assets section could set high expectations for Cytokinetics's future attractiveness, as they went to 856.3, which is a 1.8% change from the last period. These results, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. Consequently, their asset movement received a grade of 79. Also, Cytokinetics did a great job related to cash and cash equivalents this period, which stood at 115.4, representing a 2.4% change from the previous filing. Its impressive cash and cash equivalents metrics should support upward pressure on its's stock price. Consequently, their cash and cash equivalents movement received a grade of 76. At the same time, one critical balance sheet metric, Equity, was notably weak. Cytokinetics management produced disappointing equity metrics this period, which stood at 116.3, representing a -52.3% change. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. These metrics are all the more disappointing relative to their peers and should blunt potential positive momentum in its's stock price. Consequently, their equity movement received a grade of 42. Its balance sheet, therefore, earned a score of 64.

Parameter Value Change Score
Assets 856.3 1.8% 79
Liabilities 740.0 23.9% 49
Price to Book 29.9 88.5% 62
Cash & Equivalents 115.4 2.4% 76
Equity 116.3 -52.3% 42
* All values are TTM

The below chart describes Cytokinetics's performance as reflected on its balance sheet with respect to its peers. While Cytokinetics received a balance sheet score of 64, the average of its peers stands on 62.0.

  •  CYTK
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 3 1
BioNTech SE 34.0B 75 69 64 97 73 75 4 1
Seagen Inc. 32.9B 59 68 55 43 66 61 5 1
Biogen Inc. 29.7B 57 72 92 50 76 76 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 7 1
Incyte Corporation 16.8B 71 72 95 82 79 83 8 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 9 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 10 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 11 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 12 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 13 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 14 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 15 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 16 1
Alkermes plc 5.0B 63 66 46 54 71 62 17 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 18 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 19 1
Natera, Inc. 3.6B 73 65 43 95 42 54 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 21 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 22 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 23 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 25 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 27 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 29 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 30 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 31 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 32 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 33 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 35 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 36 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 37 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 38 1
Geron Corporation 566.2M 69 72 37 59 62 60 39 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 40 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 41 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 42 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 43 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 45 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 46 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Two metrics jump up as the most significant positive drivers of the income statement's strength in Cytokinetics's recent report: Revenue Efficiency and Return Factors. Cytokinetics did an excellent job managing its revenue efficiency this past period. Cytokinetics's revenue efficiency is 65.0 according to the metrics in the current filing, which represents a -7.7% change from the previous report. This parameter often affects companies in the same industry and market capitalization by up to 13.1%. Their revenue efficiency, specifically in contrast to their industry peers', should support a positive movement in the company's stock price. Consequently, their revenue efficiency received a grade of 95. Also, Return factors metrics and ratios were exceptional in this report. Cytokinetics reported a return on equity (ROE) ratio of -279.9, representing a change of -132.2% from the last report. The company appears headed in the right direction in terms of these return factors, exhibiting prudent capital expenditure growth compared to its peers. Consequently, their return factors received a grade of 73. However, one discouraging result, EBITDA, stood out. Cytokinetics's EBIDTA now sits at -193.1 and represents -20.0% change from the last reporting period. This metric might have a 24.4 percent impact on companies in the same industry and with the same market capitalization. The company's EBITDA metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Its EBITDA movement, therefore, received a grade of 50. Consequently, their income statement earned a rank of 66.

Parameter Value Change Score
EBITDA -193.1 -20.0% 50
Total Revenues 65.0 -7.7% 95
Return on Equity -279.9 -132.2% 73
* All values are TTM

The below chart describes Cytokinetics's performance as reflected on its income statement with respect to its peers. While Cytokinetics received a income statement score of 66 , the average of its peers stands on 69.0.

  •  CYTK
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 3 1
BioNTech SE 34.0B 41 89 75 79 4 1
Seagen Inc. 32.9B 54 65 70 62 5 1
Biogen Inc. 29.7B 90 57 73 70 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 7 1
Incyte Corporation 16.8B 59 77 60 73 8 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 9 1
United Therapeutics Corporation 10.6B 57 91 54 82 10 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 11 1
Exelixis, Inc. 6.7B 54 91 54 81 12 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 13 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 15 1
Ascendis Pharma A/S 5.2B 38 68 46 54 16 1
Alkermes plc 5.0B 69 55 81 62 17 1
Novavax, Inc. 4.0B 41 89 54 75 18 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 19 1
Natera, Inc. 3.6B 52 51 78 52 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 21 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 22 1
Insmed Incorporated 2.4B 51 58 73 57 23 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 25 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 27 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 28 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 29 1
IVERIC bio, Inc. 1.1B 84 58 79 70 30 1
FibroGen, Inc. 1.0B 48 74 63 67 31 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 32 1
ImmunoGen, Inc. 946.1M 40 73 71 64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 35 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 36 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 37 1
AnaptysBio, Inc. 586.3M 97 50 77 68 38 1
Geron Corporation 566.2M 89 67 73 78 39 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 40 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 41 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 42 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 43 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 45 1
Precigen, Inc. 299.1M 57 87 59 79 46 1
bluebird bio, Inc. 288.7M 99 91 61 96 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Cytokinetics appears likely to maintain its strong cash flow metrics and momentum going forward. Cytokinetics's published capital expenditures (CapEx) numbers were encouraging and reflected management's balanced change strategy. Cytokinetics recorded CapEx of -43.2, which represents 11.6% change from the previous report. The company appears to be headed in the right direction regarding resource allocation, exhibiting prudent capital expenditure growth compared to its peers. Therefore, its CapEx movement component earned a score of 89. Also, Cytokinetics did a great job related to free cash flow this period, which stood at -2.3, representing a 8.5% change from the previous filing. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.6%. Their free cash flow situation is all the more impressive relative to their peers and competitors. The company's free cash flow movement, therefore, received a grade of 79. On the other hand, Asset Turnover, jumped out as looking rather underwhelming. Cytokinetics's asset turnover metrics were concerning and highlighted potential issues management is having effectively turning assets into sales efficiently. At filing, their asset turnover metrics were 0.1, representing a -11.4% change from the previous period. Companies in the same sector and market capitalization will usually be affected by up to 4.1 percent by this parameter. Their lackluster asset turnover metrics, specifically in contrast to leading industry peers' performance, could present significant headwinds. Correspondingly, their asset turnover movement received a grade of 51. Because its management is doing an excellent job managing these critical metrics, the cash flow was given a score of 69.

Parameter Value Change Score
Net Cashflow 70.8 138.6% 63
Capital Expenditure -43.2 11.6% 89
Asset Turnover 0.1 -11.4% 51
Free Cashflow -2.3 8.5% 79
* All values are TTM

The below chart describes Cytokinetics's performance as reflected on its cash flow with respect to its peers. While Cytokinetics received a cash flow score of 69, the average of its peers stands on 68.0.

  •  CYTK
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 3 1
BioNTech SE 34.0B 73 97 50 52 72 4 1
Seagen Inc. 32.9B 53 53 50 87 58 5 1
Biogen Inc. 29.7B 58 54 90 73 66 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 7 1
Incyte Corporation 16.8B 78 79 92 74 84 8 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 9 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 10 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 11 1
Exelixis, Inc. 6.7B 79 90 89 83 87 12 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 13 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 14 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 15 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 16 1
Alkermes plc 5.0B 89 95 76 80 92 17 1
Novavax, Inc. 4.0B 62 38 63 54 60 18 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 19 1
Natera, Inc. 3.6B 52 54 56 84 58 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 21 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 22 1
Insmed Incorporated 2.4B 79 80 61 89 82 23 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 25 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 27 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 28 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 29 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 30 1
FibroGen, Inc. 1.0B 86 74 48 87 84 31 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 32 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 33 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 35 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 36 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 37 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 38 1
Geron Corporation 566.2M 78 68 49 81 77 39 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 40 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 41 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 42 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 43 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 45 1
Precigen, Inc. 299.1M 82 75 37 85 74 46 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.